Arkolith/Insider Trading/OCEL/Form 4/A

Leider Harry L.

Chief Executive Officer, DirectorOrganicell Regenerative Medicine, Inc. (OCEL) · full profile →Form 4/A · filed Dec 21, 2023
Net Buying
Open-Market Buys
$10K
Open-Market Sells
$0
Net Open-Market Flow
$10K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 29, 2023Buy(P)500K$0.01$5K1.0M
Jun 28, 2023Buy(P)549K$0.01$5K549K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4/A filing (accession 0001829126-23-008158) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4/A XML